Japan’s Eisai and U.S.-Based Nuvation Bio Secure Europe, Middle East Rights for Lung Cancer Drug in €195M Deal

Eisai and Nuvation Bio have announced an exclusive global collaboration that expands access to taletrectinib, a next‑generation therapy for ROS1‑positive non‑small cell lung cancer (NSCLC), into a wide set of regions. Under the agreement, Eisai gains rights to develop, register and commercialize the therapy across multiple territories while Nuvation Bio retains U.S. rights and continues global clinical leadership. The deal includes significant upfront and milestone payments totaling up to €195 million along with tiered royalties on future sales, reflecting strong confidence in the drug’s potential to help more patients worldwide. 

Broad Licensing Agreement Reaches Major Global Regions

The licensing agreement grants Eisai exclusive rights to taletrectinib for the treatment of ROS1‑positive NSCLC in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand and key Asia‑Pacific markets including Singapore, Indonesia, Thailand, Malaysia, Vietnam and India. Nuvation Bio will continue to manage commercial efforts in the United States and lead ongoing global development programs, maintaining its focus on U.S. launch activities and pivotal studies.

Financial terms of the agreement include an upfront payment of €50 million (approx. USD $60 million) to Nuvation Bio and potential future milestone payments of up to €145 million (approx. USD $170 million) based on regulatory and commercial achievements. In addition, Eisai will pay double‑digit royalties on taletrectinib sales in the licensed territories. Nuvation Bio is also poised to receive the first milestone payment of €25 million upon EU regulatory approval of taletrectinib.

Taletrectinib Advances Precision Therapy for ROS1‑Positive Lung Cancer

Taletrectinib, marketed as IBTROZI® in the United States and Japan, is an oral, next‑generation therapy designed to block the ROS1 protein, a key driver in a small but clinically significant subset of NSCLC patients. About 2% of all NSCLC cases are ROS1‑positive, and these patients often have few effective treatment choices after disease progression or metastasis.

In June 2025, the U.S. Food and Drug Administration granted full approval to taletrectinib for adults with locally advanced or metastatic ROS1‑positive NSCLC following Priority Review and Breakthrough Therapy designations, highlighting its potential clinical value. Taletrectinib also holds approvals in China and Japan, laying the groundwork for broader development and use.

Potential Impact on Patients and Future Development

ROS1‑positive NSCLC often affects patients at a younger age and can involve metastases to the central nervous system, making effective, targeted therapies critical for improving outcomes. Taletrectinib’s oral formulation and next‑generation design may help patients who have exhausted other treatment options or need therapies that reach difficult sites of disease.

Beyond initial approvals, ongoing clinical programs will continue to generate evidence on taletrectinib’s safety and effectiveness across various stages of disease and lines of therapy. This evidence will support regulatory expansions and help clinicians make informed decisions in clinical practice. By expanding geographic access and aligning development efforts, Eisai and Nuvation Bio aim to create a robust platform for taletrectinib’s long‑term impact on care for ROS1‑positive lung cancer. 

Author

[email protected]